Leukemické kmenové buňky a progenitory

    Školitel: MUDr. Jan Živný, Ph.D., mailto:jzivny@lf1.cuni.cz

    414

     

    Maligní nádory jsou onemocnění kmenových buněk klonálního charakteru. Skupina využívá myší model lidské kancerogeneze pro studium biologie nádorových kmenových buněk, jejich senzitivity a rezistence k experimentálním terapeutikům a pro identifikaci nových nádorových biomarkerů. Skupina se dále se zabývá analýzou buněčných mikrovezikulů produkovaných nádorovými buňkami s cílem identifikovat jejich funkci a využít je při diagnostice nádorů.

     

    Granty:

    Potenciál cirkulujících mikropartikulí a exosomů pro diagnostiku gynekologických malignit IGA NT12248-5

    Skupina se podílí na řešení projektů PRVOUK a UNCE

     

    Publikace:

    • Klener P. Jr., Anděra L., Klener P.,Nečas E., Živný J., Cell Death Signalling Pathways in the Pathogenesis and Therapy of Haematologic Malignancies: Overview of Apoptotic Pathways. Folia Biologica (Praha) 52, 34-44, 2006.
    • Vyletal P., Kublova M, Kalbacova M., Hodanova K., Baresova V, Stiburkova B., Sikora J, Hulkova H., Zivny J., Majewski J., Simmonds A., Fryns J-P. , Venkat-Raman G., Elleder M. and Kmoch S. Alterations of uromodulin biology – a common denominator of the genetically heterogeneous FJHN/MCKD syndrome. Kidney International 70, 1155–1169, 2006. doi:10.1038/sj.ki.5001728.
    • Klener P. Jr., Anděra L., Klener P.,Nečas E., Živný J., Cell Death Signalling Pathways in the Pathogenesis and Therapy of Haematologic Malignancies: Overview of Therapeutic Approaches. Folia Biologica (Praha) 52, 119-136, 2006.
    • Zivny JH, Gelderman MP, Xu F, Piper J, Holada K, Simak J, Vostal JG. Reduced erythroid cell and erythropoietin production in response to acute anemia in prion protein-deficient (Prnp-/-) mice. Blood Cells Mol Dis. 40, 302-307, 2008
    • Petrak J., Ivanek R., Toman O., Cmejla R., Cmejlova J., Vyoral D., Zivny J., Vulpe C.D. Deja vu in proteomics. A hit parade of repeatedly identified differentially expressed proteins. Proteomics, 8, 1744-1749, 2008
    • Klener P. jr., Leahomschi S., Molinsky J., Simonova T., Necas E., Gasova Z., Cermak J., Dolezalova L, Andera L., Zivny J., TRAIL-induced Apoptosis of HL60 Leukemia Cells: Two Distinct Phenotypes of Acquired TRAIL Resistance that are Accompanied with Resistance to TNF but not to Idarubicin and Cytarabine. Blood Cells Mol Dis. 42: 77-84, 2009
    • Petrak J, Toman O, Simonova T, Halada P, Cmejla R, Klener P jr., and Zivny J, Identification of molecular targets for selective elimination of TRAIL-resistant leukemia cells. From spots to in vitro assays using TOP15 charts. Proteomics (2009) 9, 1–10.
    • Pytlík R, Stehlík D, Soukup T, Kalbáčová M., Rypáček F, Trč T, Mulinková K, Michnová P, Kideryová L, Živný J, Klener P Jr., Veselá R, Trněný M, Klener P. The cultivation of human multipotent mesenchymal stromal cells in clinical grade medium for bone tissue engineering, Biomaterials, 30, 3415-3427, 2009
    • Brantova O, Asfaw B, Sladkova J, Poupetova H, Zivny J, Magner M, Krusek J, Vesela K, Hansikova, H Ledvinova J, Tesarova, M Zeman J. Ultrastructural and functional abnormalities of mitochondria in cultivated fibroblasts from alpha-mannosidosis patients. BIOLOGIA, 64 (2): 394-401, 2009
    • Zivna M, Hulkova H, Matignon M, Hodanova K, Vyletal P, Kalbacova M, Baresova V, Sikora J, Blazkova H, Zivny J, Ivanek R, Stranecky V, Sovova J, Claes K, Lerut E, Fryns JP, Hart PS, Hart TC, Adams JN, Pawtowski A, Clemessy M, Gasc JM, Gubler MC, Antignac C, Elleder M, Kapp K, Grimbert P, Bleyer AJ, Kmoch S. Dominant Renin Gene Mutations Associated with Early-Onset Hyperuricemia, Anemia, and Chronic Kidney Failure, The American Journal of Human Genetics (2009), 85, 204-213.
    • Zivny J, Klener P jr., Pytlik R, Andera L, The Role of Apoptosis in Cancer Development and Treatment: Focusing on the Development and Treatment of Hematologic Malignancies. Current Pharmaceutical Design, 2010, vol. 16, p. 11-33.
    • Grünfeld JP, Hwu W, Chien Y, Lee N, Chiang S, Dobrovolny R, Huang A, Yeh H, Chao M, Lin S, Kitagawa T, Desnick R, Hsu L, Van Keimpema L, Nevens F, Vanslembrouck R, Van Oijen G, Hoffmann A, Dekker H, De Man R, Drenth J, Alamovitch S, Plaisier E, Favrole P, Prost C, Chen Z, Van Agrmael T, Marro B, Ronco P, Zivna M, Hulkova H, Matignon M, Hodanova K, Vylet'al P, Kalbacova M, Baresova V, Sikora J, Blazkova H, Zivny J, Ivanek R, Stranecky V, Sovova J, Claes K, Lerut E, Fryns J, Hart P, Hart T, Adams J, Pawtowski A, Clemessy M, Gasc J, Gubler M, Antignac C, Elleder M, Kapp K, Grimbert P, Bleyer A, Kmoch S, Brown E, Schlöndorff J, Becker Dj, Tsukaguchi H, Uschinski A, Higgs H, Henderson J, Pollak M. More on clinical renal genetics. Clin J Am Soc Nephrol. 2010, vol. 5, p. 563-7.
    • Bleyer AJ, Živná M, Hulková H, Hodanová K, Vyletal P, Sikora J, Živný J, Sovová J, Hart TC, Adams JN, Elleder M, Kapp K, Haws R, Cornell RD, Kmoch S and Hart PS, Clinical and molecular characterization of a family with an dominant renin gene mutation and response to treatment with fludrocortisone. Clinical Nephrology, 2010; vol. 74, p. 411-422.
    • Kantele A, Häkkinen M, Zivny J, Elson CO, Mestecky J, Kantele JM. Humoral Immune Response to Keyhole Limpet Haemocyanin, the Protein Carrier in Cancer Vaccines. Clinical and Developmental Immunology 2011, vol. 2011, Article ID 614383, 6 pages, 2011. doi:10.1155/2011/614383
    • Petrak J., Sillerova T, Zivny J, and Vyoral D. Nutritional hepatic iron overload is not prevented by parenteral hepcidin substitution therapy in mice. British Journal of Nutrition, 2012, vol. 10, p. 1-3.
    • L. Lorkova, J. Pospisilova, J. Lacheta, S. Leahomschi1, J. Zivny sr., D. Cibula, J. Zivny jr. and J. Petrak: Decreased concentrations of retinol-binding protein 4 in sera of epithelial ovarian cancer patients: A potential biomarker identified by proteomics. Oncology Reports, 2012, vol. 27(2), p 318-24.
    • Molinsky J, Klanova M, Koc M, Beranova L, Andera L, Ludvikova Z, Bohmova M, Gasova Z, Strnad M, Ivanek R, Trneny M, Necas E, Zivny J, Klener P. Roscovitine sensitizes leukemia and lymphoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Leuk Lymphoma. 2013 Feb;54(2):372-80. doi: 10.3109/10428194.2012.710331. Epub 2012 Sep 8.
    • Leahomschi S, Molinsky J, Klanova M, Andera L, Peterka M, Gasova Z, Klener P Sr, Trneny M, Necas E, Simonova T, Zivny J, Klener P Jr. Multi-level disruption of the extrinsic apoptotic pathway mediates resistance of leukemia cells to TNF-related apoptosis-inducing ligand (TRAIL). Neoplasma. 2013;60(2):223-31.